grant

Toxicological and pre-clinical assessment of the anti-cancer compound Bp4eT [ 2009 - 2009 ]

Also known as: Toxicology of the anti-cancer compound Bp4eT

Funded by National Health and Medical Research Council
Managed by The University of Sydney
Managed by University of Sydney
Provided by   National Health and Medical Research Council

Research Grant

[Cite as http://purl.org/au-research/grants/nhmrc/571379]

Researchers: Prof Des Richardson (Principal investigator) ,  Dr David Lovejoy ,  Prof John Mills

Brief description Cancer cells have a high iron requirement for DNA synthesis and many clinical trials showed Fe chelators are effective anti-cancer drugs. Their potential to act as anti-tumour agents has been confirmed by the entrance of Triapine into widespread NCI clinical trials. In this NHMRC Development Grant, we will perform toxicological studies to enable clinical trials of our most promising novel iron chelator to commence.

Funding Amount $AUD 198,900.00

Funding Scheme NHMRC Development Grants

Notes Development Grant

Click to explore relationships graph
Help

Related Organisations

Related People

Subjects
Biomedical and Clinical Sciences | Cancer | Chemotherapy | Drug Development | Iron Chelators | Medical Biochemistry - Carbohydrates | Medical Biochemistry and Metabolomics | Medicinal Chemistry | Pharmaceutical Intervention | Pharmacology | Therapeutics |
Identifiers
Viewed: [[ro.stat.viewed]]
Saved to MyRDA Save to MyRDA